A randomized, double-blind, placebo-controlled, parallel group, multi-center, 2 sequential cohort Phase 2b/3 study, with a long-term extension phase, to evaluate the dose-range, and efficacy, safety and tolerability of ustekinumab compared to placebo in the treatment of subjects with newly diagnosed (3-months or less) type 1 diabetes mellitus.

Trial Profile

A randomized, double-blind, placebo-controlled, parallel group, multi-center, 2 sequential cohort Phase 2b/3 study, with a long-term extension phase, to evaluate the dose-range, and efficacy, safety and tolerability of ustekinumab compared to placebo in the treatment of subjects with newly diagnosed (3-months or less) type 1 diabetes mellitus.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 23 May 2013

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2013 Status changed from suspended to discontinued (Withdrawn during set-up) as reported by United Kingdom Clinical Research Network.
    • 04 Apr 2012 Status changed from not yet recruiting to suspended as reported by United Kingdom Clinical Research Network.
    • 11 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top